42 related articles for article (PubMed ID: 15304388)
21. EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation.
Pan J; Quintás-Cardama A; Kantarjian HM; Akin C; Manshouri T; Lamb P; Cortes JE; Tefferi A; Giles FJ; Verstovsek S
Blood; 2007 Jan; 109(1):315-22. PubMed ID: 16912224
[TBL] [Abstract][Full Text] [Related]
22. Genetic and pharmacologic evidence implicating the p85 alpha, but not p85 beta, regulatory subunit of PI3K and Rac2 GTPase in regulating oncogenic KIT-induced transformation in acute myeloid leukemia and systemic mastocytosis.
Munugalavadla V; Sims EC; Borneo J; Chan RJ; Kapur R
Blood; 2007 Sep; 110(5):1612-20. PubMed ID: 17483298
[TBL] [Abstract][Full Text] [Related]
23. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies.
Schittenhelm MM; Shiraga S; Schroeder A; Corbin AS; Griffith D; Lee FY; Bokemeyer C; Deininger MW; Druker BJ; Heinrich MC
Cancer Res; 2006 Jan; 66(1):473-81. PubMed ID: 16397263
[TBL] [Abstract][Full Text] [Related]
24. Juxtamembrane-type c-kit gene mutation found in aggressive systemic mastocytosis induces imatinib-resistant constitutive KIT activation.
Nakagomi N; Hirota S
Lab Invest; 2007 Apr; 87(4):365-71. PubMed ID: 17259998
[TBL] [Abstract][Full Text] [Related]
25. Effects of MLN518, a dual FLT3 and KIT inhibitor, on normal and malignant hematopoiesis.
Griswold IJ; Shen LJ; La Rosée P; Demehri S; Heinrich MC; Braziel RM; McGreevey L; Haley AD; Giese N; Druker BJ; Deininger MW
Blood; 2004 Nov; 104(9):2912-8. PubMed ID: 15242881
[TBL] [Abstract][Full Text] [Related]
26. KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs).
Lasota J; Miettinen M
Semin Diagn Pathol; 2006 May; 23(2):91-102. PubMed ID: 17193822
[TBL] [Abstract][Full Text] [Related]
27. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
Croom KF; Perry CM
Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228
[TBL] [Abstract][Full Text] [Related]
28. The molecular pathogenesis of gastrointestinal stromal tumors.
Tarn C; Godwin AK
Clin Colorectal Cancer; 2006 Nov; 6 Suppl 1():S7-17. PubMed ID: 17101067
[TBL] [Abstract][Full Text] [Related]
29. Imatinib mesylate (STI571) for myeloid malignancies other than CML.
Krystal GW
Leuk Res; 2004 May; 28 Suppl 1():S53-9. PubMed ID: 15036942
[TBL] [Abstract][Full Text] [Related]
30. Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options.
Demetri GD
Semin Oncol; 2001 Oct; 28(5 Suppl 17):19-26. PubMed ID: 11740803
[TBL] [Abstract][Full Text] [Related]
31. KIT mutations in mastocytosis and their potential as therapeutic targets.
Gotlib J
Immunol Allergy Clin North Am; 2006 Aug; 26(3):575-92. PubMed ID: 16931294
[TBL] [Abstract][Full Text] [Related]
32. Sensitivity of oncogenic KIT mutants to the kinase inhibitors MLN518 and PD180970.
Corbin AS; Griswold IJ; La Rosée P; Yee KW; Heinrich MC; Reimer CL; Druker BJ; Deininger MW
Blood; 2004 Dec; 104(12):3754-7. PubMed ID: 15304388
[TBL] [Abstract][Full Text] [Related]
33. The role of small molecule Kit protein-tyrosine kinase inhibitors in the treatment of neoplastic disorders.
Roskoski R
Pharmacol Res; 2018 Jul; 133():35-52. PubMed ID: 29704617
[TBL] [Abstract][Full Text] [Related]
34. Midostaurin treatment in FLT3-mutated acute myeloid leukemia and systemic mastocytosis.
Kayser S; Levis MJ; Schlenk RF
Expert Rev Clin Pharmacol; 2017 Nov; 10(11):1177-1189. PubMed ID: 28960095
[TBL] [Abstract][Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]